Notably, monoclonal antibodies targeting IL-1β (such as canakinumab) have reduced recurrent cardiovascular events in large clinical trials, despite having little direct effect on blood pressure, suggesting that inflammasome inhibition may improve hypertension-related outcomes even in the absence of antihypertensive effects per se (22). The gene discussed is IL1B; the disease is hypertensive disorder.